和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

未开盘 12-23 16:08:41

1.420

+0.080

+5.97%

最高1.480	最低1.320	成交量606.60万
今开1.340	昨收1.340	日振幅11.94%
总市值10.86亿	流通市值10.86亿	总股本7.65亿
成交额848.31万	换手率0.79%	流通股本7.65亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":1.42,"timestamp":1734941321012,"preClose":1.34,"halted":0,"volume":6066000,"delay":0,"floatShares":765000000,"shares":765000000,"eps":0.24135707,"marketStatus":"未开盘","marketStatusCode":0,"change":0.08,"latestTime":"12-23 16:08:41","open":1.34,"high":1.48,"low":1.32,"amount":8483070,"amplitude":0.119403,"askPrice":1.44,"askSize":58000,"bidPrice":1.42,"bidSize":60000,"shortable":0,"etf":0,"ttmEps":0.21756327269619005,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"listingDate":1607529600000,"adjPreClose":1.34,"openAndCloseTimeList":[[1734917400000,1734926400000],[1734930000000,1734940800000]],"volumeRatio":2.441925174283965,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142/tweets","defaultTab":"tweets","newsList":[{"id":"2493016788","title":"港股异动 | 和铂医药-B(02142)再涨近6% 近日宣布就新一代T细胞衔接器与Candid达成开发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2493016788","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493016788?lang=zh_cn&edition=full","pubTime":"2024-12-23 13:52","pubTimestamp":1734933172,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B再涨近6%，股价暂现三连阳。截至发稿，涨5.97%，报1.42港元，成交额704.9万港元。消息面上，和铂医药近日发布公告称，公司全资附属公司诺纳生物(苏州)有限公司，与Candid Therapeutics, Inc.已就开发下一代T细胞衔接器(产品)达成一项研究合作及授权协议。根据协议条款，诺纳生物有权获得首付款和潜在里程碑付款最高达3.2亿美元。Candid将负责产品的所有后续开发工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1574","02142"],"gpt_icon":0},{"id":"2493204801","title":"和铂医药－Ｂ(02142)股价上升8.955%，现价港币$1.46","url":"https://stock-news.laohu8.com/highlight/detail?id=2493204801","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493204801?lang=zh_cn&edition=full","pubTime":"2024-12-23 11:43","pubTimestamp":1734925380,"startTime":"0","endTime":"0","summary":"[上升股]和铂医药－Ｂ(02142) 股价在上午11:43比前收市价上升8.955%，现股价为港币$1.46。至目前为止，今日最高价为$1.46，而最低价为$1.32。总成交量为416.6万股，总成交金额为港币$576.455万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241223898/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1583","BK1574","02142"],"gpt_icon":0},{"id":"2493051882","title":"和铂医药-B(02142)上涨5.97%，报1.42元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2493051882","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493051882?lang=zh_cn&edition=full","pubTime":"2024-12-23 10:56","pubTimestamp":1734922574,"startTime":"0","endTime":"0","summary":"12月23日，和铂医药-B(02142)盘中上涨5.97%，截至10:56，报1.42元/股，成交460.03万元。和铂医药控股有限公司是一家全球化生物制药企业，专注于肿瘤及免疫性疾病领域的创新药研发及商业化。公司的业务包括自主研发、联合开发创新药物，对外技术授权，以及与全球顶尖学术机构及生物医药公司的创新合作。截至2024年中报，和铂医药-B营业总收入1.69亿元、净利润1014.86万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/23105646686920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02142","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2492211695","title":"和铂医药-B(02142)上涨5.74%，报1.29元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492211695","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492211695?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:38","pubTimestamp":1734586692,"startTime":"0","endTime":"0","summary":"12月19日，和铂医药-B(02142)盘中上涨5.74%，截至13:38，报1.29元/股，成交180.47万元。和铂医药控股有限公司是一家全球化生物制药企业，专注于肿瘤及免疫性疾病领域的创新药研发及商业化。公司的业务包括自主研发、联合开发创新药物，对外技术授权，以及与全球顶尖学术机构及生物医药公司的创新合作。截至2024年中报，和铂医药-B营业总收入1.69亿元、净利润1014.86万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/19133846577136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02142","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2492969511","title":"和铂医药-B盘中异动 股价大涨5.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492969511","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492969511?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:58","pubTimestamp":1734573507,"startTime":"0","endTime":"0","summary":"2024年12月19日早盘09时58分，和铂医药-B股票出现异动，股价大幅拉升5.74%。截至发稿，该股报1.290港元/股，成交量72.6万股，换手率0.09%，振幅5.74%。和铂医药-B股票所在的生物技术行业中，整体跌幅为0.77%。其相关个股中，思路迪医药股份、和铂医药-B、云康集团涨幅较大，振幅较大的相关个股有晶泰控股-P、思路迪医药股份、科济药业-B，振幅分别为13.59%、8.96%、8.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219095827ab833476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219095827ab833476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1574","02142"],"gpt_icon":0},{"id":"2492606075","title":"和铂医药-B(02142)上涨10.53%，报1.26元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492606075","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492606075?lang=zh_cn&edition=full","pubTime":"2024-12-17 11:50","pubTimestamp":1734407409,"startTime":"0","endTime":"0","summary":"12月17日，和铂医药-B(02142)盘中上涨10.53%，截至11:50，报1.26元/股，成交403.09万元。和铂医药控股有限公司是一家全球化生物制药企业，专注于肿瘤及免疫性疾病领域的创新药研发及商业化。公司的业务包括自主研发、联合开发创新药物，对外技术授权，以及与全球顶尖学术机构及生物医药公司的创新合作。截至2024年中报，和铂医药-B营业总收入1.69亿元、净利润1014.86万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/17115046460559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1574","02142","BK1583"],"gpt_icon":0},{"id":"2492672830","title":"和铂医药-B现涨超6% 就新一代T细胞衔接器与Candid达成开发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2492672830","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492672830?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:53","pubTimestamp":1734400380,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　和铂医药-B（02142）股价持续走高，上涨6.14%，现报1.21港元，成交额188.88万港元。\n　　和铂医药发布公告称，公司全资附属公司诺纳生物（苏州）有限公司（诺纳生物），与Candid Therapeutics， Inc．（Candid）已就开发下一代T细胞衔接器（产品）达成一项研究合作及授权协议。根据协议条款，诺纳生物有权获得首付款和潜在里程碑付款最高达3.2亿美元。Candid将负责产品的所有后续开发工作。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-17/doc-incztptx1871660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02142","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2492674719","title":"港股异动 | 和铂医药-B(02142)涨超5% 就新一代T细胞衔接器与Candid达成开发合作 将获最高3.2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492674719","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492674719?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:45","pubTimestamp":1734399941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B(02142)涨超5%，截至发稿，涨5.26%，报1.2港元，成交额143.5万港元。消息面上，和铂医药发布公告称，公司全资附属公司诺纳生物(苏州)有限公司(诺纳生物)，与Candid Therapeutics, Inc.(Candid)已就开发下一代T细胞衔接器(产品)达成一项研究合作及授权协议。根据协议条款，诺纳生物有权获得首付款和潜在里程碑付款最高达3.2亿美元。Candid将负责产品的所有后续开发工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1583","02142"],"gpt_icon":0},{"id":"2492867480","title":"和铂医药-B盘中异动 早盘股价大涨6.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492867480","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492867480?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:30","pubTimestamp":1734399005,"startTime":"0","endTime":"0","summary":"2024年12月17日早盘09时30分，和铂医药-B股票出现异动，股价急速上涨6.14%。截至发稿，该股报1.210港元/股，成交量8.8万股，换手率0.01%，振幅3.51%。和铂医药-B股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，和铂医药-B、复宏汉霖、华康生物医学涨幅较大，振幅较大的相关个股有和铂医药-B、科济药业-B、晶泰控股-P，振幅分别为3.51%、3.01%、1.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093005a1f46916&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093005a1f46916&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2492675006","title":"和铂医药-B公布就新一代T细胞衔接器与Candid达成开发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2492675006","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492675006?lang=zh_cn&edition=full","pubTime":"2024-12-17 08:50","pubTimestamp":1734396600,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　和铂医药-B（02142）发布公告，公司全资附属公司诺纳生物（苏州）有限公司（诺纳生物），与Candid Therapeutics， Inc．（Candid）已就开发下一代T细胞衔接器（产品）达成一项研究合作及授权协议。根据协议条款，诺纳生物有权获得首付款和潜在里程碑付款最高达3.2亿美元。Candid将负责产品的所有后续开发工作。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-17/doc-incztptx1834402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02142","BK1574","BK1583"],"gpt_icon":0},{"id":"2492067598","title":"和铂医药(02142.HK)就新一代T细胞衔接器达成开发合作 将获最高3.2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492067598","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492067598?lang=zh_cn&edition=full","pubTime":"2024-12-17 08:02","pubTimestamp":1734393720,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142.HK) 公布，旗下全资附属公司诺纳生物(苏州)，与Candid Therapeutics, Inc.已就开发下一代T细胞衔接器达成一项研究合作及授权协议。据悉，诺纳生物有权获得首付款和潜在里程碑付款最高达3.2亿美元。至于Candid将负责产品的所有后续开发工作。(js/w)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210504112141597_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210504112141597_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1404526/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02142","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2492367885","title":"智通港股早知道 | 央行会议强调适时降准降息 春节旅游产品预订量环比增长40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492367885","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492367885?lang=zh_cn&edition=full","pubTime":"2024-12-17 07:41","pubTimestamp":1734392480,"startTime":"0","endTime":"0","summary":"春节旅游产品预订量环比增长40%多家在线旅游平台和旅行社的数据显示，8天的假期激发了市民春节出游的热情，春节旅游的预订已率先启动。从团队游来看，途牛旅游网截至目前预订数据显示，12月第二周春节团期旅游产品预订量较前一周增长40%，其中，机票、酒店单项产品预订量环比增长超50%，自驾游、自由行等打包旅游产品预订量环比增长近40%。此次权益变动前，新希望化工及其一致行动人持有本行4.96%股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6f60a65603d3061b6d94114f4a555976","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","00512","BK1161","HSTECH","00772","YANG","HSCEI","06655","BK1135","BK1191","BK1130","BK1589","02142","BK1574","BK1516"],"gpt_icon":1},{"id":"2492920610","title":"和铂医药(02412.HK)就新一代T细胞衔接器与Candid达成开发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2492920610","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492920610?lang=zh_cn&edition=full","pubTime":"2024-12-17 01:47","pubTimestamp":1734371220,"startTime":"0","endTime":"0","summary":"和铂医药－Ｂ(02142.HK) 公布，全资附属诺纳生物与Candid已就开发下一代T细胞衔接器达成一项研究合作及授权协议。根据协议，诺纳生物有权获得首付款和潜在里程碑付款最高达3.2亿美元。Candid将负责产品的所有后续开发工作。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210504112142207_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210504112142207_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1404466/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02142","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2491615613","title":"昂利康获政府补助1807万元，和铂医药达成3.2亿美元BD合作，恒瑞医药1类新药纳入突破性治疗品种公示名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2491615613","media":"谈医说药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491615613?lang=zh_cn&edition=full","pubTime":"2024-12-16 23:26","pubTimestamp":1734362799,"startTime":"0","endTime":"0","summary":"根据协议条款，诺纳生物有权获得首付款和潜在里程碑付款最高达3.2亿美元。恒瑞医药：子公司苏州盛迪亚生物医药有限公司的注射用瑞康曲妥珠单抗被国家药品监督管理局药品审评中心纳入拟突破性治疗品种公示名单，公示期7日。该产品已有六个适应症获得突破性疗法认定。截至目前，注射用SHR-A1811相关项目累计已投入研发费用约7.15亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216232659ab7caeec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216232659ab7caeec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","02142","BK1574"],"gpt_icon":0},{"id":"2491126696","title":"和铂医药达成T细胞连接器研究合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2491126696","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491126696?lang=zh_cn&edition=full","pubTime":"2024-12-16 21:18","pubTimestamp":1734355080,"startTime":"0","endTime":"0","summary":"财中社12月16日电和铂医药-B（02142）发布公告称，公司全资附属公司诺纳生物（苏州）有限公司与CandidTherapeutics,Inc.达成了关于下一代T细胞连接器的研究合作及授权协议。根据协议，诺纳生物将获得首付款及潜在里程碑付款，最高可达3.2亿美元。Candid将负责该产品的后续开发工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412163269624265.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1161","BK1574","02142"],"gpt_icon":0},{"id":"2491667337","title":"和铂医药-B(02142)：就新一代T细胞衔接器与Candid达成开发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2491667337","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491667337?lang=zh_cn&edition=full","pubTime":"2024-12-16 20:07","pubTimestamp":1734350845,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，公司全资附属公司诺纳生物(苏州)有限公司(诺纳生物)，与Candid Therapeutics, Inc.(Candid)已就开发下一代T细胞衔接器(产品)达成一项研究合作及授权协议。根据协议条款，诺纳生物有权获得首付款和潜在里程碑付款最高达3.2亿美元。Candid将负责产品的所有后续开发工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)：就新一代T细胞衔接器与Candid达成开发合作","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2490710243","title":"和铂医药-B12月09日遭主力抛售42万元 环比增加2000.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490710243","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490710243?lang=zh_cn&edition=full","pubTime":"2024-12-09 16:16","pubTimestamp":1733732203,"startTime":"0","endTime":"0","summary":"12月09日, 和铂医药-B股价涨0.84%，报收1.20元，成交金额193万元，换手率0.21%，振幅2.52%，量比1.16。和铂医药-B今日主力资金净流出42万元，上一交易日主力净流出2万元，今日环比增加2000.00%。该股近5个交易日上涨1.69%，主力资金累计净流出37万元；近20日主力资金累计净流出45万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209161745ab6942c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209161745ab6942c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","02142","BK1574"],"gpt_icon":0},{"id":"2488231176","title":"和铂医药-B12月02日主力资金流出42万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2488231176","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488231176?lang=zh_cn&edition=full","pubTime":"2024-12-02 16:16","pubTimestamp":1733127375,"startTime":"0","endTime":"0","summary":"12月02日, 和铂医药-B股价涨0.85%，报收1.18元，成交金额200万元，换手率0.22%，振幅4.27%，量比1.18。和铂医药-B今日主力资金净流出42万元，连续5日净流出，上一交易日主力净流出59万元，今日环比减少28.81%。该股近5个交易日下跌1.67%，主力资金累计净流出175万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出123万元，其中净流出天数为8日。该股主力净额占比0.05%，港股市场排名2595/2649。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202161650abef2371&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202161650abef2371&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1574","02142"],"gpt_icon":0},{"id":"2486031938","title":"和铂医药累计回购412万股，占比0.536%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486031938","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486031938?lang=zh_cn&edition=full","pubTime":"2024-11-28 21:08","pubTimestamp":1732799288,"startTime":"0","endTime":"0","summary":"财中社11月28日电和铂医药-B（02142）发布公告，披露截至2024年11月28日的股份变动情况。公告显示，公司在该日期已发行股份总数为7.65亿股，其中包括回购的股份412万股。当日回购股份数量为6万股，占回购前已发行股份的0.0078%。回购股份的均价为1.18733港元，总支付金额为7万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411283253947480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1583","02142","BK1574"],"gpt_icon":0},{"id":"2486919353","title":"和铂医药-B(02142)11月28日耗资7.124万港元回购6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486919353","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486919353?lang=zh_cn&edition=full","pubTime":"2024-11-28 18:48","pubTimestamp":1732790926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)公布，2024年11月28日耗资7.124万港元回购6万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02142","BK1583"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.2456},{"period":"1month","weight":0.1639},{"period":"3month","weight":0.1833},{"period":"6month","weight":0.0365},{"period":"1year","weight":-0.0955},{"period":"ytd","weight":-0.268}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0464},{"period":"6month","weight":0.0991},{"period":"1year","weight":0.2168},{"period":"ytd","weight":0.1663}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品包括巴托利单抗，主要用于免疫性血小板减少症、甲状腺相关性眼病、重症肌无力、视神经脊髓炎谱系疾病等;以及特那西普，主要用于干眼病。此外，该公司还研究和开发肿瘤免疫产品管线，包括内部开发的新一代肿瘤免疫资产，针对治疗免疫沙漠型、免疫排斥型及炎症型肿瘤。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.111525},{"month":2,"riseRate":0,"avgChangeRate":-0.110405},{"month":3,"riseRate":0.25,"avgChangeRate":-0.124902},{"month":4,"riseRate":0.5,"avgChangeRate":0.027757},{"month":5,"riseRate":0.5,"avgChangeRate":0.040975},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069984},{"month":7,"riseRate":0.25,"avgChangeRate":0.010824},{"month":8,"riseRate":0,"avgChangeRate":-0.134459},{"month":9,"riseRate":0.25,"avgChangeRate":-0.098643},{"month":10,"riseRate":0,"avgChangeRate":-0.190485},{"month":11,"riseRate":0.75,"avgChangeRate":0.322177},{"month":12,"riseRate":0.75,"avgChangeRate":0.264125}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}